Home › This Tiny Biotech Worries Sanofi and Shire, and Vexes GlaxoSmithKline
 

Keywords :   


This Tiny Biotech Worries Sanofi and Shire, and Vexes GlaxoSmithKline

2014-12-14 16:15:36| Biotech - Topix.net

Doctors may soon have a new therapy to use when treating patients with Fabry Disease, a rare genetic disease that can result in kidney failure. That's because emerging biotech stock Amicus Therapeutics will likely be kicking itself for returning its co-commercialization rights to the drug back to Amicus last year, and for selling its equity stake in Amicus this past October.

Tags: tiny biotech worries shire

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
More »